靶向ErbB的CAR-T细胞免疫治疗癌症 - 中国病毒学论坛|我们一直在坚持！

Chimeric antigen receptor (CAR) based immunotherapy has been under development for the last 25 years and is now a promising new treatment modality in the field of cancer immunotherapy. The approach involves genetically engineering T cells to target malignant cells through expression of a bespoke fusion receptor that couples an HLA-independent antigen recognition domain to one or more intracellular T-cell activating modules. Multiple clinical trials are now underway in several centers to investigate CAR T-cell immunotherapy of diverse hematologic and solid tumor types. The most successful results have been achieved in the treatment of patients with B-cell malignancies, in whom several complete and durable responses have been achieved. This review focuses on the preclinical and clinical development of CAR T-cell immunotherapy of solid cancers, targeted against members of the ErbB family.

嵌合抗原受体(CAR)为基础的免疫治疗已经发展了将近25年了，并且现在在癌症免疫治疗领域，已经成为一种很有前途的新的治疗方式。这种方法涉及了一个靶向肿瘤细胞的修饰过的T细胞，通过T细胞表面表达一种定制的融合受体，受体包含了一个HLA独立抗原识别领域，能够引起一个或多个细胞内的T细胞激活模块。在几个中心的多中心临床试验正在进行中，以探讨CAR-T技术对不同的血液和实体肿瘤的免疫治疗作用。在治疗B细胞恶性肿瘤的患者中已经取得了最成功的结果，已经出现不少完整和持久的反应。本文综述了对抗实体癌症，针对ErbB家族成员的CAR-T细胞免疫疗法的临床前和临床开发。